US3773951A

US3773951A - Method of treating depression with 1-(2-pyridyl)piperazine

Info

Publication number: US3773951A
Application number: US00317133A
Authority: US
Inventors: R Rodriguez
Original assignee: Miles Laboratories Inc
Current assignee: Bayer Corp
Priority date: 1972-12-21
Filing date: 1972-12-21
Publication date: 1973-11-20
Anticipated expiration: 1990-11-20

Abstract

ADMINISTRATION OF 1-(2-PYRIDYL)PIPERAZINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF IS DISCLOSED AS A CHEMOTHERAPEUTIC METHOD OF TREATING MANIFESTATIONS OF DEPRESSION IN EXPERIMENTAL MAMMALS. DAILY DOSES RANGING FROM 2 MG./KG. TO 60 MG./KG. PER DAY ARE CONSIDERED EFFECTIVE.

Description

United States Patent 3,773,951 METHOD OF TREATING DEPRESSION WITH 1-(2-PYRIDYL)PIPERAZINE Rodolfo Rodriguez, Mexico City, Mexico, assiguor to Miles Laboratories, Inc., Elkhart, Ind. No Drawing. Filed Dec. 21, 1972, Ser. No. 317,133 Int. Cl. A61k 27/00 US. Cl. 424-250 2 Claims ABSTRACT OF THE DISCLOSURE Administration of 1-(2-pyridyl)piperazine or a pharmaceutically acceptable acid addition salt thereof is disclosed as a chemotherapeutic method of treating manifestations of depression in experimental mammals. Daily doses ranging from 2 mg./kg. to 60 mg./kg. per day are considered effective.

BACKGROUND OF THE INVENTION Field of the invention Depression is a psychiatric condition which may be diagnosed as a symptom, a syndrome, or a disease entity, depending upon the clinical situation of the patient. Although there is a lack of uniformity in classification, depression is clinically differentiated as reactive (interchangeably used with neurotic depression) or endogenous (also referred to as psychotic or involutional depression). Regardless of etiology, antidepressant drugs are a common form of therapy, and the disclosed new use of 1-(2- pyridyl)piperazine is a chemotherapeutic method of treating depression.

DESCRIPTION OF THE PRIOR ART Antidepressant drugs fall into three broad categories of monoamine oxidase (MAO) inhibitors, certain tricyclic compounds, and amphetamine-like drugs.

Among MAO inhibitors still in current use are isocarboxazide, nialimide, phenylzine, and tranylcypromine. Use of these compounds, however, is gradually becoming disfavored because their relatively low eflicacy is countervailed by their relatively high toxicity. The most dangerous toxic elfects caused by this class of drugs include hepato-toxicity, excessive central stimulation, orthostatic hypotension, and interaction with other drugs.

More widely used in depression is a family or tricyclic compounds including imipramine, desmethylimipramine, and amitriptyline. Although these drugs are more efiective than MAO inhibitors and less toxic, they nevertheless cause a variety of untoward side eifects. Among the latter are: atropine-like effects, including dryness of the mouth, constipation, dizziness, tachycardia, palpitations, and blurred vision; various cardiovascular difficulties, including orthostatic hypotension, myocardial infarction, arrhythmias, and tachycardia; persistent tremor; and psychiatric efiects, such as a transition from depression to hypomanic or manic excitement, and hallucinations.

Although characterized as noncatecholamine sympathomimetic drugs, amphetamine sulfate, methamphetamine, and methylphenodate are effective in treating endogenous depression and the depressive phase of certain types of schizophrenia. In cases of chronic depression, tolerance is developed to the central efiects of amphetamines, and the user often increases the dose to obtain the desired elfect. Among other undesirable features are: abnormal mental conditions such as paranoid delusions and hallucinations; central effects, including restlessness, dizziness, tremor, hyperactive reflexes, irritability, insomnia, and tenseness; and gastrointestinal effects, as anorexin, nausea, emesis, and diarrhea.

For a discussion of antidepressant drugs, refer to: Jarvik, Muray E., Drugs Used in the Treatment of Psy- 3,773,951 Patented Nov. 20, 1973 chiatric Disorders, III. Drugs for Affective Disorders (Depression and Mania), in The Pharmacological Basis of Therapeutics, 4th ed., L. S. Goodman and A. Gilman, editors, New York, Macmillan, 1970, chapter 12, pp. 181- 192; and Innes, Ian R. and Nickerson, Mark, Drugs Acting on Postganglionic Andrenergic Nerve Endings and Structures Innervated by Them (Sympathomimetic Drugs), H. Noncatecholamines, op. cit., chapter 24, pp. 500-520.

The compound 1-(2-pyridyl)piperazine is not related to the drugs described above and has the following structural formula:

The synthesis of 1-(2-pyridyl)piperazine is described by Hamlin et al. in J. Am. Chem. Soc. 71:2731-2743 (1949) and by Howard et al. in J. Org. Chem., 18:1484-1488 (1953). In the publication by Howard, 1-(2-pyridyl)piperazine was reported to have no analgesic or antifilarial activity. Although L. W. Roth in I. Pharmac. Exp. Ther., 110: 157-165 (1954) reported the pharmacological activity of a series of substituted piperazines, 1-(2-pyridyl piperazine was not tested.

SUMMARY OF THE INVENTION The essential feature of this discovery is the utility of 1 (2 pyridyl)piperazine (hereinafter called compound A for convenience) in the treatment of depression as a symptom, syndrome, or a disease entity. Administration of an eflective amount of compound A, generally in daily doses of from 2 mg./kg. to 60 mg./kg., produces an antidepressant effect in experimental animals. Pharmaceutically acceptable acid addition salts of compound A can be used in lieu of the parent compound. In comparative tests with imipramine as a reference, compound A exhibits greater eflicacy than the reference drug.

Dose forms of compound A can be conveniently prepared by the addition of pharmaceutically acceptable vehicles generally used in formulations. Dose forms can be prepared in. a solid or liquid state by methods known in the art for oral, intravenous, parenteral, intramuscular, and subcutaneous administration.

DESCRIPTION OF THE PREFERRED EMBODIMENTS Example 1 The method of treating depression by administering 1- (2-pyridyl)piperazine to rats in an experimental model of depression is assessed according to the procedure developed by Horovitz et al., described in Int. J. NeuropharmacoL, 5:405-411 (1966). The basis of this procedure is the neuropharmacological effect of antidepressant drugs in suppressing the spontaneous killing of mice (muricide) by selective killer rats. This muricide test has gained wide recognition among neuropharmacologists to test compounds for treating depression.

Killer rats of both sexes are easily ascertained as those which kill mice consistently within 5 seconds after confrontation. Experimental drugs are tested by observation of muricide responses at 15 minute intervals after intraperitoneal administration of the drugs. Table I summ'arizes the results of the muricide test for 1 (2- pyridyl)piperazine dihydrocbloride and a reference compound, imipramine, 5 (3 dimethylaminopropyl) 10,11- dihydro 5H dibenz[b,f]azepine (US. Pat. No. 2,554,736, 1951). The median'effective dose and confidence limits are represented by the standard abbreviations ED and C1 respectively. The number of rats observed is indicated under the column N.

Example 2 Because depression of the muricide response may be symptomatic of motor impairment, the method of treating depression by administering 1 (2 pyridyl)piperazine dihydrochloride was also evaluated by the rotarod test of Dunham and Miya described in I. Am. Pharm. Assoc. (sci. ed.), 46:208-209 (1957). In this test, rats are trained to walk for periods of 100 seconds on a wooden rod rotating at 13 r.p.m. After intraperitoneal administration of a drug walking times are recorded at zero time and at various 15 minute intervals afterwards.

Table II summarizes the result of the rotarod test for 1 (2 pyridyl)piperazine dihydrochloride and the reference drug imipramine.

The specificity of the anti-muricidal eifect is measured by calculating the ratio of the rotarod ED to the anti muricide ED A ratio significantly greater than 1 indicates a specific anti-muricidal effect at non-debilitating doses. The ratio of rotarod ED to antimuricidal ED for 1 (2 pyridyl)piperazine dihydrochloride is 16.4, substantially in excess of unity, whereas the respective ratio for imipramine is 1.5.

The median lethal dose (LD in mg./kg.) for 1-(2- pyridyl) piperazine dihydrochloride in rats is 681 mg./ kg.

What is claimed is:

1. A method of treating a mammal having a symptom, a syndrome or a disease entity characterized as depression, which comprises:

administering to said mammal an effective amount of a compound selected from the group consisting essentially of 1 (2 pyridyl)piperazine and a pharmaceutically acceptable acid addition salt thereof.

2. A method as in claim 1, wherein said compound is 1-(2-pyridy1)piperazine dihydrochloride.

References Cited UNITED STATES PATENTS 2,606,906 8/1952 Hultquist 260-268 2,958,694 11/1960 Ianssen 424-250 STANLEY J. FRIEDMAN, Primary Examiner